JP2011519868A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519868A5
JP2011519868A5 JP2011507707A JP2011507707A JP2011519868A5 JP 2011519868 A5 JP2011519868 A5 JP 2011519868A5 JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011519868 A5 JP2011519868 A5 JP 2011519868A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
inhibitor
drug
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011507707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/042657 external-priority patent/WO2009137378A2/en
Publication of JP2011519868A publication Critical patent/JP2011519868A/ja
Publication of JP2011519868A5 publication Critical patent/JP2011519868A5/ja
Withdrawn legal-status Critical Current

Links

JP2011507707A 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与 Withdrawn JP2011519868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040508P 2008-05-05 2008-05-05
US61/050,405 2008-05-05
PCT/US2009/042657 WO2009137378A2 (en) 2008-05-05 2009-05-04 Sequential administration of chemotherapeutic agents for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2011519868A JP2011519868A (ja) 2011-07-14
JP2011519868A5 true JP2011519868A5 (cg-RX-API-DMAC7.html) 2012-06-07

Family

ID=40940448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507707A Withdrawn JP2011519868A (ja) 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与

Country Status (6)

Country Link
US (1) US20110129456A1 (cg-RX-API-DMAC7.html)
EP (1) EP2282739A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011519868A (cg-RX-API-DMAC7.html)
CA (1) CA2722992A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010012064A (cg-RX-API-DMAC7.html)
WO (1) WO2009137378A2 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
JP2010514801A (ja) 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ, インコーポレイテッド ロミデプシンの精製
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2259797A2 (en) * 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
ME02377B (me) 2008-12-12 2016-06-20 Boehringer Ingelheim Int Anti-igf antitijela
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
AU2011223883B2 (en) * 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
JP5909239B2 (ja) 2010-10-26 2016-04-26 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
US20130231346A1 (en) * 2010-11-17 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US9993480B2 (en) * 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SG11201507234UA (en) * 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
HRP20210338T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije fgfr-i cmet-inhibitora za liječenje raka
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CN106456648B (zh) * 2014-03-26 2021-11-02 阿斯特克斯治疗有限公司 Fgfr抑制剂和igf1r抑制剂的组合
US10555931B2 (en) 2014-05-28 2020-02-11 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
HRP20210440T1 (hr) 2014-10-29 2021-04-30 Five Prime Therapeutics, Inc. Kombinirana terapija za rak
KR102309882B1 (ko) * 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
TWI725966B (zh) 2015-04-13 2021-05-01 戊瑞治療有限公司 癌症組合療法
LT3353164T (lt) 2015-09-23 2022-01-25 Janssen Pharmaceutica, N.V. Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui
AU2016328692B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv New compounds
CA3003271A1 (en) * 2015-10-30 2017-05-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108601839B (zh) * 2015-11-03 2021-10-26 基因泰克公司 用于治疗癌症的Bcl-2抑制剂和MEK抑制剂组合产品
RS61996B1 (sr) 2016-12-22 2021-07-30 Calithera Biosciences Inc Kompozicije i postupci za inhibiranje aktivnosti arginaze
CN110636867B (zh) * 2017-05-21 2023-09-05 Igf肿瘤公司 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗csf1rおよび抗pd−1抗体組合せ併用療法
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor

Similar Documents

Publication Publication Date Title
JP2011519868A5 (cg-RX-API-DMAC7.html)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2011515478A5 (cg-RX-API-DMAC7.html)
JP2019503674A5 (cg-RX-API-DMAC7.html)
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2012247438A5 (cg-RX-API-DMAC7.html)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
US10544222B2 (en) PD1/CTLA4 binders
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
US9388239B2 (en) Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CA2718918A1 (en) Methods for treating or preventing colorectal cancer
JP2014516964A5 (cg-RX-API-DMAC7.html)
JP2014516964A (ja) 治療用抗igf1r合剤
JP2017538673A5 (cg-RX-API-DMAC7.html)
NZ561648A (en) Methods and composition of IGF1R inhibitors for treating or preventing cancer
JPWO2021055705A5 (cg-RX-API-DMAC7.html)